Press release
Cancer Biological Therapy Market Emerging Growth by Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Seattle Genetics an
Some of the eminent industry players operating in cancer biological therapy industry includes AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals and Takeda Pharmaceuticals. Key industry players implement several strategies such as mergers, acquisition, geographic expansions and new product launch that enables them to achieve sustainable profits.
Request a sample of this premium report titled at https://www.marketstudyreport.com/request-a-sample/467761/?utm_source=OPNPR-VarsH
Increasing R&D funding by government in various pharmaceutical, biopharmaceutical companies as well as research institutes involved in developing cancer drugs will foster cancer biologics market growth. Funds raised by governments in developed countries such as UK have facilitated cancer drug discovery process and has also enhanced operational capabilities of the companies and research centers involved in developing cancer biological therapy drugs and vaccines. Moreover, favorable government policies and regulatory framework facilitating drug discovery process will substantially augment cancer biologics industry growth. However, adverse effects of anti-cancer drug therapy may lower its preference and hamper business growth up to some extent.
Receiving FDA approvals for newly developed drugs will also foster company?s revenue generation. For instance, in November 2018, Roche and Abbvie received FDA approval for Venclexta, a BCL-2 inhibitor effective in the treatment of leukemia. Venclexta is jointly commercialized by Abbvie and Genetech, a part of Roche Group in the U.S. and is sold solely by Abbvie outside of the U.S. Receiving approvals for new drugs will boost Abbvie?s as well as Roche?s profits.
Growing geriatric population will drive cancer biological therapy industry growth during forecast timeframe. Elderly population in the age group of 50 years and above is more susceptible to cancer that escalates demand for cancer biologic therapies. Cancer biological therapy is utilized to boost immune system and has commendable specificity that helps in faster recovery. High preference for cancer biological therapy for treating geriatric population suffering from cancer will positively influence industry growth over forthcoming years.
Vaccines segment was valued at USD 2.0 billion in 2017 and is expected to have considerable revenue size over forthcoming years. Vaccines utilized in cancer treatment possess high efficiency and have ability to increase immunity by recognizing and destroying specific antigens. Moreover, vaccines also create immunogenic response that reduces risk of acquiring cancer again in future and are most effective in treatment of bladder, breast and cervical cancer. Aforementioned factors coupled with growing incidences of breast cancer in developing economies such as India will stimulate segmental growth.
India cancer biological therapy market accounted for 18.3% revenue share in 2017 and is anticipated to have exponential growth during forecast timeframe. According to WHO, cancer is one of major causes of mortality and morbidity in India. Furthermore, availability of efficient cancer biological therapy has considerably increased survival rate in cancer patients. Aforementioned factors along with growing awareness regarding cancer treatment amongst people residing in rural India will trigger Indian cancer biological therapy industry growth during analysis period.
Germany cancer biological therapy market was valued at USD 4.0 billion in 2017. Increasing prevalence of cancer in Germany will surge demand for cancer biologics therapy. High prevalence of cancer will propel demand for cancer biologics thereby, enhancing Germany cancer biologics industry growth.
Request a discount on standard prices of this premium report titled at https://www.marketstudyreport.com/check-for-discount/467761
Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Cancer biological therapy industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Cancer Biological Therapy Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing incidence of cancer worldwide
3.3.1.2. Growing geriatric population
3.3.1.3. Technological advancement in cancer biologics in developed countries
3.3.1.4. Increasing R&D funding coupled with favorable government policies
3.3.2. Industry pitfalls and challenges
3.3.2.1. High cost of treatment
3.3.2.2. Adverse effects of anti-cancer drug therapy
3.4. Growth potential analysis
3.4.1. By product
3.5. Porter's analysis
3.6. Competitive landscape, 2017
3.6.1. Strategy dashboard
3.7. PESTEL analysis
Chapter 4. Cancer Biological Therapy Market, By Product
4.1. Key segment trends
4.2. Monoclonal antibodies (MAB)
4.2.1. Market size, by region, 2013 - 2024
4.2.2. Naked MAB
4.2.2.1. Market size, by region, 2013 - 2024
4.2.3. Conjugated MAB
4.2.3.1. Market size, by region, 2013 - 2024
4.2.4. Bispecific MAB
4.2.4.1. Market size, by region, 2013 - 2024
4.3. Vaccines
4.3.1. Market size, by region, 2013 - 2024
4.3.2. Preventive vaccines
4.3.2.1. Market size, by region, 2013 - 2024
4.3.3. Therapeutic vaccines
4.3.3.1. Market size, by region, 2013 - 2024
4.4. Cancer growth blockers
4.4.1. Market size, by region, 2013 - 2024
4.4.2. Tyrosine kinase Inhibitors (TKI)
4.4.2.1. Market size, by region, 2013 - 2024
4.4.3. Proteasome Inhibitors (PI)
4.4.3.1. Market size, by region, 2013 - 2024
4.4.4. mTOR Inhibitors
4.4.4.1. Market size, by region, 2013 - 2024
4.5. Blood cell growth factors (BCGF)
4.5.1. Market size, by region, 2013 - 2024
4.5.2. Lenograstim
4.5.2.1. Market size, by region, 2013 - 2024
4.5.3. Filgrastim
4.5.3.1. Market size, by region, 2013 - 2024
4.6. Cytokines
4.6.1. Market size, by region, 2013 - 2024
4.6.2. Interferons
4.6.2.1. Market size, by region, 2013 - 2024
4.6.3. Interleukins
4.6.3.1. Market size, by region, 2013 - 2024
Chapter 5. Cancer Biological Therapy Market, By Region
5.1. Key regional trends
5.2. North America
5.2.1. Market size, by country 2013 - 2024
5.2.2. Market size, by product, 2013 - 2024
5.2.2.1. Market size, by MAB, 2013 - 2024
5.2.2.2. Market size, by vaccines, 2013 - 2024
5.2.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.2.5. Market size, by cytokines, 2013 - 2024
5.2.3. U.S.
5.2.3.1. Market size, by product, 2013 - 2024
5.2.3.1.1. Market size, by MAB, 2013 - 2024
5.2.3.1.2. Market size, by vaccines, 2013 - 2024
5.2.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.3.1.5. Market size, by cytokines, 2013 - 2024
5.2.4. Canada
5.2.4.1. Market size, by product, 2013 - 2024
5.2.4.1.1. Market size, by MAB, 2013 - 2024
5.2.4.1.2. Market size, by vaccines, 2013 - 2024
5.2.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.4.1.5. Market size, by cytokines, 2013 - 2024
5.3. Europe
5.3.1. Market size, by country 2013 - 2024
5.3.2. Market size, by product, 2013 - 2024
5.3.2.1. Market size, by MAB, 2013 - 2024
5.3.2.2. Market size, by vaccines, 2013 - 2024
5.3.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.2.5. Market size, by cytokines, 2013 - 2024
5.3.3. Germany
5.3.3.1. Market size, by product, 2013 - 2024
5.3.3.1.1. Market size, by MAB, 2013 - 2024
5.3.3.1.2. Market size, by vaccines, 2013 - 2024
5.3.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.3.1.5. Market size, by cytokines, 2013 - 2024
5.3.4. UK
5.3.4.1. Market size, by product, 2013 - 2024
5.3.4.1.1. Market size, by MAB, 2013 - 2024
5.3.4.1.2. Market size, by vaccines, 2013 - 2024
5.3.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.4.1.5. Market size, by cytokines, 2013 - 2024
5.3.5. France
5.3.5.1. Market size, by product, 2013 - 2024
5.3.5.1.1. Market size, by MAB, 2013 - 2024
5.3.5.1.2. Market size, by vaccines, 2013 - 2024
5.3.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.5.1.5. Market size, by cytokines, 2013 - 2024
5.3.6. Spain
5.3.6.1. Market size, by product, 2013 - 2024
5.3.6.1.1. Market size, by MAB, 2013 - 2024
5.3.6.1.2. Market size, by vaccines, 2013 - 2024
5.3.6.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.6.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.6.1.5. Market size, by cytokines, 2013 - 2024
5.3.7. Italy
5.3.7.1. Market size, by product, 2013 - 2024
5.3.7.1.1. Market size, by MAB, 2013 - 2024
5.3.7.1.2. Market size, by vaccines, 2013 - 2024
5.3.7.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.7.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.7.1.5. Market size, by cytokines, 2013 - 2024
5.4. Asia Pacific
5.4.1. Market size, by country 2013 - 2024
5.4.2. Market size, by product, 2013 - 2024
5.4.2.1. Market size, by MAB, 2013 - 2024
5.4.2.2. Market size, by vaccines, 2013 - 2024
5.4.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.2.5. Market size, by cytokines, 2013 - 2024
5.4.3. India
5.4.3.1. Market size, by product, 2013 - 2024
5.4.3.1.1. Market size, by MAB, 2013 - 2024
5.4.3.1.2. Market size, by vaccines, 2013 - 2024
5.4.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.3.1.5. Market size, by cytokines, 2013 - 2024
5.4.4. China
5.4.4.1. Market size, by product, 2013 - 2024
5.4.4.1.1. Market size, by MAB, 2013 - 2024
5.4.4.1.2. Market size, by vaccines, 2013 - 2024
5.4.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.4.1.5. Market size, by cytokines, 2013 - 2024
5.4.5. Japan
5.4.5.1. Market size, by product, 2013 - 2024
5.4.5.1.1. Market size, by MAB, 2013 - 2024
5.4.5.1.2. Market size, by vaccines, 2013 - 2024
5.4.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.5.1.5. Market size, by cytokines, 2013 - 2024
5.5. Latin America
5.5.1. Market size, by country 2013 - 2024
5.5.2. Market size, by product, 2013 - 2024
5.5.2.1. Market size, by MAB, 2013 - 2024
5.5.2.2. Market size, by vaccines, 2013 - 2024
5.5.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.2.5. Market size, by cytokines, 2013 - 2024
5.5.3. Brazil
5.5.3.1. Market size, by product, 2013 - 2024
5.5.3.1.1. Market size, by MAB, 2013 - 2024
5.5.3.1.2. Market size, by vaccines, 2013 - 2024
5.5.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.3.1.5. Market size, by cytokines, 2013 - 2024
5.5.4. Argentina
5.5.4.1. Market size, by product, 2013 - 2024
5.5.4.1.1. Market size, by MAB, 2013 - 2024
5.5.4.1.2. Market size, by vaccines, 2013 - 2024
5.5.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.4.1.5. Market size, by cytokines, 2013 - 2024
5.5.5. Mexico
5.5.5.1. Market size, by product, 2013 - 2024
5.5.5.1.1. Market size, by MAB, 2013 - 2024
5.5.5.1.2. Market size, by vaccines, 2013 - 2024
5.5.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.5.1.5. Market size, by cytokines, 2013 - 2024
5.6. MEA
5.6.1. Market size, by country 2013 - 2024
5.6.2. Market size, by product, 2013 - 2024
5.6.2.1. Market size, by MAB, 2013 - 2024
5.6.2.2. Market size, by vaccines, 2013 - 2024
5.6.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.2.5. Market size, by cytokines, 2013 - 2024
5.6.3. South Africa
5.6.3.1. Market size, by product, 2013 - 2024
5.6.3.1.1. Market size, by MAB, 2013 - 2024
5.6.3.1.2. Market size, by vaccines, 2013 - 2024
5.6.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.3.1.5. Market size, by cytokines, 2013 - 2024
5.6.4. Saudi Arabia
5.6.4.1. Market size, by product, 2013 - 2024
5.6.4.1.1. Market size, by MAB, 2013 - 2024
5.6.4.1.2. Market size, by vaccines, 2013 - 2024
5.6.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.4.1.5. Market size, by cytokines, 2013 - 2024
5.6.5. UAE
5.6.5.1. Market size, by product, 2013 - 2024
5.6.5.1.1. Market size, by MAB, 2013 - 2024
5.6.5.1.2. Market size, by vaccines, 2013 - 2024
5.6.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.5.1.5. Market size, by cytokines, 2013 - 2024
Complete report titled at https://www.marketstudyreport.com/reports/cancer-biological-therapy-market
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
Contact Us:
Market Study Report
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biological Therapy Market Emerging Growth by Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Seattle Genetics an here
News-ID: 1681768 • Views: …
More Releases from marketstudyreport.com
Load Bank Market Growth Prospectus by 2028 - Business Opportunities by ASCO Powe …
A concise assortment of data on the 'Load Bank Market' offers an exhaustive study targeting current market trends influencing the business across assorted regions. Significant details related to market size, market share, applications, and statistics are put together to convey an ensemble prediction of the industry. The research further focuses on comprehensive competitor analysis in addition to highlighting growth strategies embraced by market leaders.
Load Bank Market Size was estimated…
Agriculture Equipment Market is Expected to Reach USD 161640 Million by 2028 - J …
Global Agriculture Equipment Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of the market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
Global Agriculture Equipment Market Size was estimated at USD 114110 million in 2021 and is projected to reach USD 161640 million by 2028, exhibiting a CAGR of…
Electric Vehicle Market Size to grow at a CAGR of 23.5% through 2028| Tesla Inc. …
Global Electric Vehicle Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
The electric vehicles (EVs) market is estimated to witness a robust growth rate of 23.5% during the period 2019-2028.
The operation is done to stop ligament tears and…
Fuel Cell Air Compressor Market is Expected to Reach USD 512.3 Million by 2028 - …
Global Fuel Cell Air Compressor Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
Global Fuel Cell Air Compressor Market Size was estimated at USD 215.1 million in 2021 and is projected to reach USD 512.3 million by 2028, exhibiting…
More Releases for MAB
mAb Biosimilars Market Thrives as Cost-effective Alternatives Fuel Adoption | Sa …
mAb Biosimilars Market Overview
mAb Biosimilars Market is estimated to grow from USD 9.4 billion in 2025 to USD 22.7 billion by 2032, at a CAGR of 13.3%.
Coherent Market Insights is pleased to release its latest mAb Biosimilars Market research report, offering an in-depth analysis of the U.S. mAb Biosimilars Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels, encompassing supply chain shifts, payer-provider…
Anti-PD-1 MAb Market - Demand And Segments, Size Analysis Forecast to 2028
The immune system has an important ability to differentiate between normal cells in the body from those it sees as "foreign." This helps the immune system attack foreign cells without harming the normal cells by using "checkpoints." Immune checkpoints are molecules on specific immune cells that must be activated (or inactivated) to start an immune response. Cancer cells use these checkpoints to avoid immune system attacks on them. Certain drugs…
Investigation announced for Investors in I-Mab (NASDAQ: IMAB) concerning potenti …
An investigation was announced for current long-term investors in shares of I-Mab (NASDAQ: IMAB) over potential breaches of fiduciary duties by certain directors at I-Mab .
Investors who purchased shares of I-Mab (NASDAQ: IMAB) and currently hold any of those I-Mab (NASDAQ: IMAB shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain I-Mab directors…
Anti-PD-1 MAb Market 2020 Size, Share, Comprehensive Research, Significant Porti …
The Anti-PD-1 MAb Market research report provides an in depth examination of the key factors stimulating market expansion. It also sheds light on the challenges or restraining factors that are poised to hinder industry growth over the forecast timeframe. Growth rate, market share captured, and valuation estimates for each region, segment, and company are documented as well.
The immune system has an important ability to differentiate between normal cells in the…
Anti-PD-1 MAb Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Anti-PD-1 MAb market analysis, which studies the Anti-PD-1 MAb's industry coverage, current market competitive status, and market outlook and forecast by 2025.
Global “Anti-PD-1 MAb Market 2020-2025” Research Report categorizes the global Anti-PD-1 MAb market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth…
Puzzle Pieces Marketing Lends our Fab President to the MAB
SAN DIEGO, CA - October 23, 2018 - Puzzle Pieces Marketing is excited to announce that our very own, Angel Mason Broadus, is now a part of the Point Loma Nazarene University (PLNU) Marketing Advisory Board (MAB).
The MAB is a team of marketing professionals, representing a diverse span of marketing careers and organizations, serving to provide input and direction to the faculty, and opportunities for the students. The formation of…
